|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.588 EUR | +0.76% |
|
+5.31% | -0.87% |
| 07-21 | Innate Pharma Completes Enrollment in Dose Escalation of Phase 1 Study of IPH4502 | CI |
| 07-21 | Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bullish | Neutral |
| Resistance | 1.604 | 1.96 | 2.01 |
| Spread/Res. | -1.00% | -18.98% | -21.00% |
| Spread/Supp. | +5.73% | +12.62% | +47.86% |
| Support | 1.502 | 1.41 | 1.074 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- IPH Stock
- Charts Innate Pharma
Select your edition
All financial news and data tailored to specific country editions
